Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD0055 dose-blinded extension of orchestra (PD0053) with minzasolmin in Parkinson’s disease
2022-500424-30-00Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Minzasolmin with Placebo (2 arms). Primary endpoint: Baseline-adjusted DaT-SPECT whole striatum specific binding ratio at Month 18. Started Nov 2022; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2022-500424-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500424-30-00.